CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 66 enrolled
Drug / intervention
LY3074828 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03662100
NCT03662100Phase 1Completed

A Safety, Tolerability, and Pharmacokinetic Study of Injections of LY3074828 Solution Using Investigational 1-mL Pre-filled Syringes and Investigational 2-mL Autoinjector in Healthy Subjects

Eli Lilly and Company·interventional·Posted Sep 7, 2018·Updated Jan 25, 2024

In Brief

A Phase 1 clinical trial evaluating LY3074828, Auto-injector (AI), and 1 other intervention for Healthy. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given as different formulations. The tolerability of LY3074828 will also be evaluated and information about any side effects experienced will be collected. Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 12 weeks, not including screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedSep 7, 2018
Enrollment StartSep 6, 2018
Primary CompletionJan 25, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.8 years ago

Interventions

LY3074828biological

Administered SC

LY3074828drug

Administered SC

Auto-injector (AI)device

AI to administer LY3074828

Prefilled syringe (PFS)device

PFS to administer LY3074828